2024-03-06 07:20:44 ET
Summary
- The FTC is requesting more information on the merger between Cerevel Therapeutics and AbbVie.
- Concerns may be focused on the Phase 3 treatment Tavapadon for Parkinson's disease.
- The market expects a 75% chance of the acquisition going through, which could be too low of an expectation considering some of the facts.
- We'd pass, because the downside is high if anything were to go wrong, and there are unknowns here, but we see the value in this for some intrepid traders.
...
Read the full article on Seeking Alpha
For further details see:
Cerevel Therapeutics: Parkinson's Could Be The Issue